SUN PHARMACEUTICAL INDUSTRIES Financial Statement Analysis
|
||
|
The Revenues of SUN PHARMACEUTICAL INDUSTRIES have increased by 13.53% YoY .
The Earnings Per Share (EPS) of SUN PHARMACEUTICAL INDUSTRIES has increased by 158.94 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
SUN PHARMACEUTICAL INDUSTRIES Last 5 Annual Financial Results
[BOM: 524715|NSE : SUNPHARMA]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹43,886 Cr | ₹38,654 Cr | ₹33,498 Cr | ₹32,838 Cr | ₹29,066 Cr |
| Expenses | ₹32,424 Cr | ₹28,773 Cr | ₹25,030 Cr | ₹25,863 Cr | ₹22,792 Cr |
| Operating Profit (Excl OI) | ₹11,461 Cr | ₹9,882 Cr | ₹8,468 Cr | ₹6,974 Cr | ₹6,274 Cr |
| Other Income | ₹820 Cr | ₹1,437 Cr | ₹859 Cr | ₹652 Cr | ₹1,059 Cr |
| Interest | ₹172 Cr | ₹127 Cr | ₹141 Cr | ₹303 Cr | ₹555 Cr |
| Depreciation | ₹2,529 Cr | ₹2,144 Cr | ₹2,080 Cr | ₹2,053 Cr | ₹1,753 Cr |
| Profit Before Tax | ₹9,408 Cr | ₹4,481 Cr | ₹2,799 Cr | ₹5,010 Cr | ₹3,810 Cr |
| Profit After Tax | ₹8,561 Cr | ₹3,406 Cr | ₹2,285 Cr | ₹4,187 Cr | ₹3,209 Cr |
| Consolidated Net Profit | ₹8,474 Cr | ₹3,273 Cr | ₹2,904 Cr | ₹3,765 Cr | ₹2,665 Cr |
| Earnings Per Share (Rs) | ₹35.32 | ₹13.64 | ₹12.10 | ₹15.69 | ₹11.11 |
| PAT Margin (%) | 11.53 | 5.07 | 3.72 | 7.05 | 5.70 |
| ROE(%) | 16.46 | 7.21 | 4.98 | 9.66 | 8.05 |
| ROCE(%) | 17.24 | 9.28 | 5.66 | 10.07 | 8.68 |
| Total Debt/Equity(x) | 0.11 | 0.02 | 0.08 | 0.18 | 0.25 |
Key Financials |
||
| Market Cap | : | ₹ 360,914.7 Cr |
| Revenue (TTM) | : | ₹ 47,444.6 Cr |
| Net Profit(TTM) | : | ₹ 8,998.6 Cr |
| EPS (TTM) | : | ₹ 37.5 |
| P/E (TTM) | : | 40.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
| CIPLA | 4.1% | -4.8% | 55.6% |
| DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
| ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
| DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
| MANKIND PHARMA | 1.3% | 7% | NA |
| TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
| LUPIN | 0.6% | 0.5% | 127.2% |
| AUROBINDO PHARMA | 5.1% | 10.9% | 87.1% |
SUN PHARMACEUTICAL INDUSTRIES Revenues
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 13.53 % |
| 5 Yr CAGR | 10.85 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹43,886 Cr | 13.53 | |
| Mar2022 | ₹38,654 Cr | 15.39 | |
| Mar2021 | ₹33,498 Cr | 2.01 | |
| Mar2020 | ₹32,838 Cr | 12.98 | |
| Mar2019 | ₹29,066 Cr | - | |
SUN PHARMACEUTICAL INDUSTRIES Operating Profit
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 15.99 % |
| 5 Yr CAGR | 16.26 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹11,461 Cr | 15.99 | |
| Mar2022 | ₹9,882 Cr | 16.70 | |
| Mar2021 | ₹8,468 Cr | 21.42 | |
| Mar2020 | ₹6,974 Cr | 11.17 | |
| Mar2019 | ₹6,274 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 2.19 % |
| 5 Yr CAGR | 4.89 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 26.12% | 2.19 | |
| Mar2022 | 25.56% | 1.11 | |
| Mar2021 | 25.28% | 19.02 | |
| Mar2020 | 21.24% | -1.58 | |
| Mar2019 | 21.58% | - | |
SUN PHARMACEUTICAL INDUSTRIES Profit After Tax
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 158.91 % |
| 5 Yr CAGR | 33.53 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹8,474 Cr | 158.91 | |
| Mar2022 | ₹3,273 Cr | 12.70 | |
| Mar2021 | ₹2,904 Cr | -22.87 | |
| Mar2020 | ₹3,765 Cr | 41.25 | |
| Mar2019 | ₹2,665 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 127.42 % |
| 5 Yr CAGR | 19.26 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 11.53 % | 127.42 | |
| Mar2022 | 5.07 % | 36.29 | |
| Mar2021 | 3.72 % | -47.23 | |
| Mar2020 | 7.05 % | 23.68 | |
| Mar2019 | 5.7 % | - | |
SUN PHARMACEUTICAL INDUSTRIES Earnings Per Share (EPS)
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 158.94 % |
| 5 Yr CAGR | 33.53 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹35 | 158.94 | |
| Mar2022 | ₹14 | 12.73 | |
| Mar2021 | ₹12 | -22.88 | |
| Mar2020 | ₹16 | 41.22 | |
| Mar2019 | ₹11 | - | |
SUN PHARMACEUTICAL INDUSTRIES Return on Capital Employed (ROCE)
[BOM: 524715|NSE : SUNPHARMA]
| Y-o-Y | 85.78 % |
| 5 Yr CAGR | 18.71 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 17.24% | 85.78 | |
| Mar2022 | 9.28% | 63.96 | |
| Mar2021 | 5.66% | -43.79 | |
| Mar2020 | 10.07% | 16.01 | |
| Mar2019 | 8.68% | - | |
SUN PHARMACEUTICAL INDUSTRIES Share Price vs Sensex
| Current Share Price | : | ₹1,504.3 |
| Current MarketCap | : | ₹ 360,914.7 Cr |
| Updated EOD on | : | Apr 26,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUN PHARMACEUTICAL INDUSTRIES | -2.3% |
-6.5% |
55.3% |
| SENSEX | 0.9% |
1.5% |
23.6% |
SUN PHARMACEUTICAL INDUSTRIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 3% | 4% | 55.2% |
| S&P BSE DIVIDEND STABILITY | 2.9% | 4.3% | 58.7% |
| S&P BSE ALLCAP | 2.3% | 5% | 41.4% |
| S&P BSE 500 SHARIAH | 2.1% | 2.7% | 40.2% |
| MFG | 2.1% | 3.8% | 44% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY HEALTHCARE | 3.2% | 2.5% | 51.3% |
| NIFTY PHARMA | 3.2% | 2.2% | 51.4% |
| NIFTY500 MULTICAP 50:25:25 | 2.8% | 6.7% | 49.4% |
| NIFTY ALPHA LOW-VOLATILTY 30 | 2.8% | 2.8% | 54.7% |
| NIFTY LARGE MIDCAP 250 | 2.7% | 5.5% | 46.4% |
You may also like the below Video Courses
FAQ about SUN PHARMACEUTICAL INDUSTRIES Financials
How the annual revenues of SUN PHARMACEUTICAL INDUSTRIES have changed ?
The Revenues of SUN PHARMACEUTICAL INDUSTRIES have increased by 13.53% YoY .
How the Earnings per Share (EPS) of SUN PHARMACEUTICAL INDUSTRIES have changed?
The Earnings Per Share (EPS) of SUN PHARMACEUTICAL INDUSTRIES has increased by 158.94 % YoY .
Check out Intrinsic Value of Peers of SUN PHARMACEUTICAL INDUSTRIES
Compare Stock Analytics of Peers of SUN PHARMACEUTICAL INDUSTRIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
